



BIOMIMETICS SYMPATHIES Inc.

Company Description

We work to contribute to a better future by delivering regenerative medicine to patients.

We know that the treatment of intractable diseases also results in our happiness. In research and development to deliver promising cellular medicinal products to patients as early as possible, we see it as important to understand the law according to which cells efficiently function.

We provide seven exceptional features through Animal Origin-Free (AOF) medium technology.

- Excellent therapeutic efficacy
- Secure regenerative medicine with no risk of infections
- Efficient cellular medicine development and gene therapy products services
- Sustained production of homogeneous cells
- Development of "Designed MSCs"
- Stable global supply of media
- Exosomes and culture conditioned medium

Basic technology

Designed MSC" optimized for each disease

The serum-free nature enables modification of a variety of cellular characteristics.

In addition, a library of chemicals to produce cells with modified characteristics enables selection of the best cells for target diseases.

Culture technology with specifications necessary for clinical practice

A culture system that is free from human / animal-derived components throughout all processes.

This system is characterized by media showing excellent cell growth.

Exosome & culture conditioned medium

Our culture conditioned medium, which are characterized by the safety of AOF and high content of exosomes, have proven to be effective in multiple disease animal models. Their use as samples for research will provide strong support for development.

Intellectual property strategy

Our culture conditioned medium, which are characterized by the safety of AOF and high content of exosomes, have proven to be effective in multiple disease animal models. Their use as samples for research will provide strong support for development.

Business

Clinical development

「Mesenchymal Stem Cells (MSCs)」

Mesenchymal stem cells have potential for effective treatments in various disease areas, such as cardiovascular diseases, central nervous system diseases, autoimmune disorders, gastrointestinal diseases, and respiratory diseases, and are increasingly developed and put to practical use around the world. We will work on the expansion of our development pipeline, beginning at systemic sclerosis and infertility, for which no effective treatment is available.

License business

For mesenchymal stem cells under development, BioMimetics Sympathies licenses the rights for the development, manufacture, and sales in Japan and overseas or work on joint development. We address consultations about licenses by indication, area, and right from development seeds before proceeding to clinical studies to the development stage after proceeding to clinical studies.

In addition, we accept consultations about the license or transfer of know-how and patents owned by us.

Business development consulting

BioMimetics Sympathies provides business development consulting in the development of new businesses / development of medical devices.

We provide total support for the development and promotion of new businesses by creating a business concept, developing a business / action plan, and establishing an alliance system as the foundation for business operation and a cooperation system with medical institutions / doctors.

Sales of cosmetic ingredients

- Exosome-based drug discovery support
- Development of digital medicine

- Development of medical devices addressing unmet medical needs
- Development of VR-based training programs

Regenerative medicine support business

We provide support related to the design of cell-processing centers (CPCs), facility management, training, and submission of a plan to provide regenerative medicine for medical institutions providing regenerative medicine or companies entrusted as specified cell-processing business operators with cell cultures under the Act on the Safety of Regenerative Medicine.

- Support in developing a plan to provide regenerative medicine
- Support for facility management and personnel training
- Provision of technology

Company Details**Head Office**

Japan

Main Business

細胞性医薬品に関する研究開発と臨床開発、再生医療に関する製品、知的財産及び権利のライセンス導出、再生医療技術を基盤とする化粧品事業、再生医療関連ビジネスの事業開発、再生医療支援、医療機器開発支援

President

漆畑 直樹

Established

2000年11月28日

Capital

17億8,330万円（2019年3月現在）

Number of Employees

11 - 50

URL

<https://www.bm-s.biz/>

Offices**Main Office**

19F Time24 building
2-4-32 Aomi, Koto-ku
Tokyo, Japan, 1350064